SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

Infinite Money Glitch ($IMG.X) is trending as holders tout receiving $SOL.X rewards directly into their wallets just for holding, with the community emphasizing the ease and passive income potential of the token. Discussions highlight the strength and resilience of the community, especially after recent changes and new developments, with a bare knuckle fight sponsorship with Kimbo Slice Jr. also generating buzz.

Aventus

Aventus is trending as the community focuses on its low market cap relative to its presence on Coinbase, fueling discussions about potential for significant growth.  Enthusiastic users are coordinating to drive up the price, while others highlight its partnerships and technology. Some traders are hoping for a breakout to reach $3.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as its community rallies around token burns tied to watcher milestones, fueling excitement and perceived scarcity. Talk centers on the strong community, the potential for significant upside, and a desire to reach number one on trending lists. The coin is built on the Solana network and the community is anticipating airdrop details.

Wayfinder

Wayfinder's PROMPT.X is trending with community members citing potential breakouts and significant gains, with some suggesting accumulation during dips. Bullish sentiment is fueled by mentions of strong support levels and potential short squeezes, while others point to increased volume and a possible reversal after a period of decline. The coin is being compared to other altcoins, with some speculating on potential future price targets.

its a Meme token and beta to Troll The "Lenny face  is a text-based emoticon, ( ͡° ͜ʖ ͡°), used to convey a range of emotions, particularly mischief, sexual innuendo, or a hidden meaning. It's often employed in online discussions to add a playful or suggestive tone to a message, or sometimes even to spam threads, according to Wikipedia. The symbol is visually interpreted as a face with two eyes (small circles), a nose (squiggly line), and a mouth (curved line).

Lenny

$LENNY.X is trending as community members rally around the meme coin, emphasizing its strong cult following and potential for significant growth. Recent attention from a prominent figure (

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

PEPE.X is trending as the community discusses potential moves in meme coins and altcoins. Some users are weighing PEPE.X against newer coins, while others are debating whether to buy the dip or take profits. Overall, community sentiment seems mixed.

Emulites

Emulites is trending as community members express strong bullish sentiment and highlight the project's potential. Comparisons are being made to other recent meme coin successes, with some anticipating similar gains. The coin is being touted as a promising opportunity within the meme coin space.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending as community members discuss its potential for long-term growth and recovery, particularly highlighting the new CEO's vision and execution. There's chatter around its current valuation, competition with brands like Lululemon, and potential catalysts like the upcoming World Cup and new product lines. Some investors are also discussing whether recent price movements are indicative of a larger turnaround or a temporary fluctuation.

Memecoin on Injective taken over by the community.

Nonja

Nonja ($NONJA.X) is trending as community members highlight its strong connection to Injective ($INJ.X) and the potential benefits from the anticipated INJ Staked ETF. The conversation emphasizes Nonja's strong community, unique art, and a significant portion of its market cap burned to the liquidity pool. Many believe Nonja has the potential for amplified gains as Injective gains broader recognition.

Pump.fun

$PUMP.X is trending as community members discuss its potential for significant gains, with some highlighting its strong chart and recent updates. Conversations also mention the coin's resilience and potential breakout, with many expressing excitement about its future prospects within the Solana ecosystem. Some users suggest this could be a long-term play, while others are actively trading the volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NVO Wins FDA Approval for MASH Treatment: ETFs Likely to Gain

NVO rose about 4% on Aug. 18, 2025, after Wegovy won FDA approval as the first GLP-1 therapy for MASH, expanding its reach beyond obesity and diabetes. NVO-heavy ETFs like OZEM, THNR and PPH should benefit from this trend. 

ETFs in Focus on Eli Lilly's Solid Q2 Earnings, Weak Obesity Data

LLY tumbles despite solid Q2 results. ETFs like IHE, PPH, MEDX and MEDI with top exposure may offer buy-the-dip opportunities.

ETFs to Capitalize on the Novo Nordisk-Septerna Deal

Eli Lilly shares rose more than 1% premarket Thursday, on track to hit levels last seen in late October, as the pharmaceutical giant posted stronger-than-expected earnings and revenue despite another sales miss for its obesity and diabetes drugs.The company reported Q4&nbsp;earnings per share (EPS) of $5.32, beating the $5.08 consensus estimate, while revenue came in at $13.53 billion, topping Wall Street’s $13.43 billion forecast.&nbsp;Sales of its blockbuster GLP-1 drugs Zepbound and Mounjaro surged but came in slightly below expectations, weighed down by lower realized prices.&nbsp;Mounjaro generated $3.53 billion in revenue, a 60% jump from the prior year but short of analysts’ $3.62 billion estimate. Zepbound posted $1.91 billion in sales, missing the $1.98 billion forecast.&nbsp;This marks the second consecutive quarter where both drugs have fallen short of estimates, according to <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2025/02/06/eli-lilly-lly-earnings-q4-2024.html">CNBC</a>.Older diabetes medicines outperformed expectations, helping offset the shortfall in Lilly’s newer treatments.&nbsp;CEO David Ricks called 2024 a highly successful year, highlighting major clinical readouts for tirzepatide in treating chronic diseases tied to obesity, billions in manufacturing expansion, and the launch of Alzheimer’s drug Kisunla and dermatitis medication Ebglyss as key drivers of long-term growth.&nbsp;“We enter 2025 with tremendous momentum and look forward to strong financial performance and several important Phase 3 readouts which, if positive, will further accelerate our long-term growth,” he added.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Eli_Lilly_sentiment_and_message_volume_Feb_6_premarket_0e4b15d3e8.png" alt="Eli Lilly sentiment and message volume Feb 6 premarket.png" width="1318" height="324"><figcaption>Eli Lilly sentiment and message volume Feb 6 premarket as of 8 am ET | source: Stocktwits</figcaption></figure>On Stocktwits, Eli Lilly was among the top 10 trending tickers ahead of Thursday’s opening, with sentiment turning more bullish.&nbsp;Optimistic traders pointed to the earnings beat and expected continued strength, with one eyeing a move past $900.&nbsp;<stembedurl>https://stocktwits.com/Zukio/message/603106677</stembedurl>Another said hedge funds and institutional investors would likely drive the&nbsp;actual move during market hours.<stembedurl>https://stocktwits.com/nat9co/message/603108641</stembedurl>For 2025, Eli Lilly expects EPS between $22.50 and $24.00, compared to the $22.69 consensus estimate, and projects revenue between $58 billion and $61 billion, surpassing Wall Street’s $58.91 billion forecast.&nbsp;The company is ramping production to meet soaring demand, estimating it will manufacture at least 1.6 times the number of incretin doses in the first half of 2025 compared to a year ago.&nbsp;Lilly also announced plans to report late-stage data for its next-generation obesity drug retatrutide later this year, ahead of schedule.As of Wednesday’s close, <a href="https://stocktwits.com/symbol/LLY">Eli Lilly’s stock</a> was up nearly 8% year to date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Eli Lilly and Company logo seen displayed on a smartphone. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

Eli Lilly's Blockbuster Obesity Drugs Miss Sales Estimates Again, But Investors Cheer Q4 Earnings Beat

Older diabetes medicines outperformed expectations, helping offset the shortfall in Lilly’s newer treatments.

Equity

Older diabetes medicines outperformed expectations, helping offset the shortfall in Lilly’s newer treatments.


Roundhill Investments Surpasses $4 Billion AUM Milestone

Roundhill Investments Surpasses $4 Billion AUM Milestone Roundhill Investments Surpasses $4 Billion AUM Milestone PR Newswire NEW YORK, Jan. 16, 2025 NEW YORK, Jan. 16, 2025 /PRNewswire/ -- Roundhill...

Eli Lilly &amp; Co. (LLY) shares rose 0.3% premarket Wednesday, bouncing slightly after Tuesday's steep 6%&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lly-stock-falls-on-q4-weight-loss-drug-sales/chG8mwrRVc">plunge</a> — the worst session for the stock in nearly four years.&nbsp;The selloff followed the drugmaker's disappointing fourth-quarter (Q4) revenue guidance, with significant misses in sales for its blockbuster weight-loss and diabetes drugs, Mounjaro and Zepbound.However, several Wall Street analysts expressed optimism, suggesting the dip could offer an attractive entry point for investors.Leerink noted Lilly lowered its Q4 revenue guidance by 5% but issued a 2025 revenue forecast 2% above its consensus, according to The Fly. The brokerage maintained its 'Outperform' rating, citing long-term growth potential and a promising pipeline.BofA Securities reiterated a 'Buy' rating with a $997 price target,&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.investing.com/news/stock-market-news/eli-lilly-bofa-says-buy-the-dip-after-shares-slide-on-q4-miss-3813128">according</a> to Investing.com. Analyst Tim Anderson emphasized that despite short-term challenges, Lilly remains a dominant player in the "diabesity" market with significant growth opportunities.JPMorgan's Chris Schott reportedly called the stock dip following the Q4 sales miss a buying opportunity, highlighting Lilly's strong 2025 positioning, expanded market presence, and anticipated 60% growth in sellable doses of incretins in the first half of 2025.Mizuho's Jared Holz&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.google.com/search?q=eli+lilly+mizuho&amp;oq=eli&amp;gs_lcrp=EgZjaHJvbWUqBggAEEUYOzIGCAAQRRg7MgYIARBFGDsyBggCEEUYOzITCAMQLhiDARjHARixAxjRAxiABDIGCAQQRRg5MgYIBRBFGDwyBggGEEUYPDIGCAcQRRg90gEINjAxMGowajeoAgCwAgA&amp;sourceid=chrome&amp;ie=UTF-8">told</a> CNBC that "some of the supply commentary from the company makes a lot of sense" and highlighted the nascent stage of the obesity market. However, he flagged valuation as a concern, with Lilly trading at 32 times 2025 earnings estimates—higher than most large-cap pharma peers.Retail message volume on Stocktwits about Lilly jumped over 240% on Tuesday.&nbsp;<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/LLY_sentiment_and_message_volume_Jan_15_premarket_8c6741e2bb.png" alt="LLY sentiment and message volume Jan 15 premarket.png" width="1318" height="324"><figcaption>LLY sentiment and message volume Jan 15 premarket as of 8 am ET | source: Stocktwits</figcaption></figure>Heading into Wednesday, sentiment on the platform remained 'bullish,' as watchers took cues from analyst optimism and kept faith in long-term prospects for Lilly's weight-loss and diabetes drugs remain intact.<a href="https://stocktwits.com/symbol/LLY">Eli Lilly's stock</a> is down 4.5% year-to-date but has gained over 16% in the past 12 months. The company will report fourth-quarter and full-year results next month.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Eli Lilly Gets Wall Street Backing After Tuesday’s Turmoil, Stock Rises Premarket As Retail Stays Bullish

JPMorgan's Chris Schott reportedly called the stock dip following the Q4 sales miss a buying opportunity.

Eli Lilly Recovers Premarket As Analysts Defend Stock After Tuesday’s Slide, Retail Bullish

Shares of Eli Lilly &amp; Co. dropped over 7% on Tuesday morning, reaching levels last seen in late November and marking the&nbsp;stock’s worst day since March 15, 2021.&nbsp;The decline followed a disappointing fourth-quarter revenue outlook update, particularly from its blockbuster weight-loss and diabetes drugs, Mounjaro and Zepbound.The company now forecasts full-year revenue of about $45 billion, down from its previous range of $45.4 billion-$46 billion and below the consensus of $45.55 billion.&nbsp;Fourth-quarter revenue is expected to be approximately $13.5 billion, falling short of the $13.93 billion consensus.&nbsp;Sales of Mounjaro totaled $3.5 billion, below the $4.4 billion estimate, while Zepbound brought in $1.9 billion, missing expectations of $2.14 billion.CEO David A. Ricks attributed the shortfall to slower-than-expected growth in the U.S. incretin market, compounded by lower year-end channel inventory. Incretins like GLP-1 are used in diabetes and obesity drugs such as Mounjaro and Zepbound.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/LLY_sentiment_and_message_volume_Jan_14_082f836502.png" alt="LLY sentiment and message volume Jan 14.png" width="1318" height="324"><figcaption>LLY sentiment and message volume Jan 14 as of 12:15 pm ET | source: Stocktwits</figcaption></figure>However, retail sentiment on Stocktwits stayed ‘extremely bullish,’ with the ticker climbing to the top five trending symbols list amid a spike in message volume.&nbsp;Many retail investors considered the dip an overreaction, expressing optimism for 2025 projections and hinting they were buying the dip.<stembedurl>https://stocktwits.com/ChrisH76/message/599965534</stembedurl><stembedurl>https://stocktwits.com/NastyPelosi/message/599965487</stembedurl><stembedurl>https://stocktwits.com/OldFagGuy/message/599960901</stembedurl><stembedurl>https://stocktwits.com/JackCoLu/message/599959582</stembedurl>Lilly expects continued growth for Mounjaro and Zepbound in 2025, supported by expanded manufacturing capacity and new market launches.&nbsp;The company plans to increase production of tirzepatide by at least 60% in the first half of 2025 compared to the same period in 2024.Lilly anticipates revenue contributions from new drugs, including oncology treatment Jaypirca, dermatitis medication Ebglyss, Crohn’s disease therapy Omvoh, and Alzheimer’s drug Kisunla.&nbsp;Additionally, the company is pursuing approvals for new indications of existing medicines and potential launches, such as imlunestrant for metastatic breast cancer.Lilly expects its experimental weight-loss pill, orforglipron, to receive approval as early as next year, CEO David Ricks&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-01-13/lilly-sees-new-weight-loss-pill-approval-in-early-2026-ceo-says?sref&amp;">revealed</a> during an interview with Bloomberg TV at the JPMorgan Healthcare Conference in San Francisco on Monday. Data on the pill is expected by mid-2025.Lilly’s stock has gained over 16% in the past year but is down nearly 5% in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mounjaro manufactured by Eli Lilly and Company packaging is seen in this illustration photo taken in a pharmacy in Krakow, Poland on April 9, 2024. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Eli Lilly Stock Faces Worst Day In Nearly 4 Years On Q4 Weight-Loss Drug Sales Miss, But Retail Bullish On 2025 Projections

The pharma giant expects continued growth for Mounjaro and Zepbound this year, supported by expanded manufacturing capacity and new market launches.  

Shares of Eli Lilly &amp; Co. (<a class="mention" data-mention="$LLY" data-symbol-id="LLY" href="https://stocktwits.com/symbol/LLY" target="_blank">$LLY</a>) and Novo Nordisk A/S (<a class="mention" data-mention="$NVO" data-symbol-id="NVO" href="https://stocktwits.com/symbol/NVO" target="_blank">$NVO</a>) climbed in Tuesday’s premarket trading after the Biden administration announced a proposal to provide Medicare and Medicaid coverage for obesity drugs.In a statement released early Tuesday, the White House said, "The proposed rule would be implemented at the same time as a comprehensive agenda to lower the costs of drugs, including the drug price negotiation program and increased market competition."An analysis by the Department of Health and Human Services (HHS) found that obesity drug pricing in the international market is much lower than in the U.S., the&nbsp; White House release said.&nbsp;"It’s unacceptable that Americans – especially those without insurance coverage for these drugs — are forced to pay so much more for life-saving medications," it added.Currently, anti-obesity medications are given Medicare and Medicaid coverage&nbsp;only&nbsp;for certain conditions like diabetes.&nbsp;"Today’s new proposal would expand access to these innovative medications for obesity, which is widely recognized as a disease, and help an estimated 3.4 million Americans with Medicare," the release said.The Biden administration expects the coverage to reduce out-of-pocket costs of these prescription drugs by as much as 95% for some enrollees. It sees about 4 million adult Medicaid enrollees to gain new access to these medications.The new proposal will override the previous legislation passed 20 years ago, prohibiting Medicare coverage for weight-loss drugs.The proposal has to be endorsed by the incoming Trump administration to become a law.&nbsp; The proposition looks&nbsp;like&nbsp;a tall order as President-elect Donald Trump has nominated&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-names-anti-vaxxer-robert-kennedy-as-health-and-human-services-secretary-here-s-what-it-means-for-healthcare-stocks/cJ4F4ofRfY">Robert Kennedy Jr.</a>, who is very vocal with his opposition to these medications, to lead HHS.&nbsp;Novo Nordisk and Lilly are leaders in the weight-loss drug category, with their Wegovy and Zepbound, respectively. Both are injectable formulation of drugs belonging to a class of medications called GLP-1 agonists. These work by reducing the appetite, slowing the release of food from the stomach and increasing the feeling of fullness after eating.&nbsp;Novo Nordisk’s Wegovy sales jumped 79% year-over-year in the third quarter to $2.5 billion and Lilly’s Zepbound sales came in at $1.26 billion.On Stocktwits, retail sentiment toward both Novo Nordisk and Lilly remained stuck at "neutral."In premarket trading, as of 7:48&nbsp;a.m. ET, Novo Nordisk shares climbed 2.62% to $107.30, and Lilly jumped 4.90% to $792.For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/zoom-video-reports-beat-and-raise-q3-2025/cJIWZvyRgq">Zoom Video Stock Slumps Despite Beat-and-Raise Q3 But Retail Stays Connected</a>

The Biden administration expects the coverage to reduce out-of-pocket costs of obesity drugs by as much as 95% for some enrollees.

Eli Lilly, Novo Nordisk Shares Climb Premarket As Biden Administration Mulls Medicare, Medicaid Coverage For Obesity Drugs: Retail Unmoved

The new proposal would expand access to medications for obesity, and help an estimated 3.4 million Americans with Medicare. 

Danish diabetes drug maker Novo Nordisk A/S ($NVO), which shot to prominence with its Wegovy weight-loss drug, reported Wednesday strong sales and earnings growth for the third quarter.Novo Nordisk reported third-quarter net profit 27.30 billion Danish Kroner ($3.92 billion), up 21% year-over-year (Y-o-Y), as sales also rose by a similar magnitude to 71.31 billion Danish Kroner (DKK).&nbsp;The top-line, however, came in below the 72.3 billion DKK-consensus estimate, according to Reuters, amid softer-than-expected diabetes drug sales.Wegovy sales jumped 79% YoY to 17.30 DKK ($2.5 billion), ahead of the 15.9 billion DKK forecast by analysts.Wegovy is a once-weekly injectable formulation of Novo Nordisk’s diabetes drug semaglutide, marketed as Ozempic. It was approved by the FDA in 2021 for chronic weight management in adults with obesity or overweight with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol.Novo Nordisk’s diabetes franchise fetched sales of 47.94 billion DKK, up 13% YoY.Looking ahead, the company said it expects 2024 sales to rise at a currency-neutral rate of 23-27%, and operating profit to grow by 21%-27%.The company is now evaluating a two-drug combo treatment candidate by the name CagriSema, for obesity, and a late-stage readout for the drug is expected later this year.As of 10:53 am ET, the stock fell 1.91% to $108.03.<figure class="image"><a href="https://stocktwits.com/symbol/NVO"><img style="aspect-ratio:646/140;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/nvo_sentiment_0ac0560a3f.png" alt="nvo-sentiment.png" width="646" height="140"></a><figcaption>NVO sentiment and message volume November 6, 2024, &nbsp;as of 10:53 am ET | Source:&nbsp;Stocktwits</figcaption></figure>Retail sentiment toward Novo Nordisk stock was 'bullish' (72/100), with message volume rising to ‘extremely high’ level.A retailer said on the Stocktwits platform that he was buying the dip.<stembedurl>https://stocktwits.com/Sasquamch/message/591414857</stembedurl>Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/exact-sciences-reports-double-miss-for-q3/cJ4RtWFR9Y">Exact Sciences Stock Plunges After Q3 Miss, Guidance Cut: Retail Stays Mostly Positive</a>For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;

Novo Nordisk Q3 earnings and revenue climbed by double-digit percentages.

Novo Nordisk Stock Falls Despite Strong Q3 Weight-Loss Drug Sales: Retail Shrugs Off Weakness

: Novo Nordisk’s injectable weight-loss drug Wegovy sales climbed 79% year-over-year but overall sales growth was a touch soft.

Novo Nordisk’s injectable weight-loss drug Wegovy sales climbed 79% year-over-year but overall sales growth was a touch soft.


Roundhill Investments Launches GLP-1 & Weight Loss ETF (OZEM)

Roundhill Investments Launches GLP-1 & Weight Loss ETF (OZEM) Roundhill Investments Launches GLP-1 & Weight Loss ETF (OZEM) PR Newswire NEW YORK, May 21, 2024 OZEM provides exposure to the rapidly...

OZEM
Roundhill GLP-1 & Weight Loss ETF

Feed

News

Sentiment

Fundamentals

Info

Latest OZEM News

OZEM Roundhill GLP-1 & Weight Loss ETF